Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onureg pharmacokinetics in hepatic impairment
NCT05209295Phase 1Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of CC-486 in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML) and 2 more (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time Zero to Last Measured Time Point at Day 1, Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity at Day 1 and 1 more. Started Jul 2024; status: terminated.
02
Drugs
CC-486
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)chronic myelomonocytic leukemia (CMML)myeloproliferative neoplasms (MPN)Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Beyond the preview
Go deeper on NCT05209295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05209295.